Scholarlink

Background <p>Osteosarcoma is a highly aggressive primary bone malignancy in which distant metastasis critically determines patient prognosis. However, the molecular drivers of metastasis remain incompletely understood, making the elucidation of these drivers a research priority.</p> Methods <p>We integrated single-cell and bulk RNA sequencing data to identify cell populations associated with metastasis and to screen for candidate therapeutic targets. Bioinformatics tools predicted upstream transcriptional regulators. Functional roles and transcriptional regulation were assessed via wound-healing, Transwell, and luciferase reporter assays.</p> Results <p>Single-cell analysis of osteosarcoma heterogeneity identified the osteoblastic subcluster C2_OB as a major contributor to metastasis. cNMF analysis defined a metastasis-associated expression program (module 2) highly active in C2_OB, within which S100A13 emerged as a novel signature gene. S100A13 was overexpressed in osteosarcoma and correlated with metastasis and poor prognosis. Functional assays demonstrated that S100A13 promoted cell migration and invasion. Mechanistically, the transcription factor SP1 directly binds to the S100A13 promoter, activates its transcription, and thereby enhances the metastatic capacity of osteosarcoma cells.</p> Conclusion <p>This study identifies S100A13 as a biomarker for osteosarcoma metastasis and poor prognosis, and delineates an SP1/S100A13 axis that drives metastatic progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

S100A13 transcriptionally activated by SP1 facilitates osteosarcoma metastasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Fuxing Tang,
  • Yisheng Wang,
  • Tao Feng,
  • Shuheng Zhou,
  • Xianghong Zeng,
  • Piwei Huang,
  • Jinhui Peng,
  • Bowei Liang

摘要

Background

Osteosarcoma is a highly aggressive primary bone malignancy in which distant metastasis critically determines patient prognosis. However, the molecular drivers of metastasis remain incompletely understood, making the elucidation of these drivers a research priority.

Methods

We integrated single-cell and bulk RNA sequencing data to identify cell populations associated with metastasis and to screen for candidate therapeutic targets. Bioinformatics tools predicted upstream transcriptional regulators. Functional roles and transcriptional regulation were assessed via wound-healing, Transwell, and luciferase reporter assays.

Results

Single-cell analysis of osteosarcoma heterogeneity identified the osteoblastic subcluster C2_OB as a major contributor to metastasis. cNMF analysis defined a metastasis-associated expression program (module 2) highly active in C2_OB, within which S100A13 emerged as a novel signature gene. S100A13 was overexpressed in osteosarcoma and correlated with metastasis and poor prognosis. Functional assays demonstrated that S100A13 promoted cell migration and invasion. Mechanistically, the transcription factor SP1 directly binds to the S100A13 promoter, activates its transcription, and thereby enhances the metastatic capacity of osteosarcoma cells.

Conclusion

This study identifies S100A13 as a biomarker for osteosarcoma metastasis and poor prognosis, and delineates an SP1/S100A13 axis that drives metastatic progression.